November 2020 Midatech Pharma PLC ("Midatech" or the "Company") MTX110 Phase I Trial Results in DIPG and Preclinical Efficacy Data in Glioblastoma presented at 2020 Annual SNO Conference Midatech Pharma PLC (AIM: MTPH.L;

("Midatech" or the "Company")

MTX110 Phase I Trial Results in DIPG

Preclinical Efficacy Data in Glioblastoma

at 2020 Annual SNO Conference

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:

MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to note

that the latest research on MTX110 was presented by its collaborators at the recent annual meeting of the Society of Neuro-Oncology

(SNO2020 Virtual Conference). Links to the Abstracts and Posters are provided below:

PNOC015: An Open Label Single Arm Phase

I/II Study of MTX110 Delivered by Convection-Enhanced Delivery (CED) in Patients with Diffuse Intrinsic Pontine Glioma (DIPG) Previously

Treated with External Beam Radiation Therapy (ABSTRACT DDRE-21) - Lead Author: Dr Sabine Mueller, Pacific Pediatric Neuro-Oncology

The Abstract may be found at:

The Poster may be found at:

Efficacy of Soluble Panobinostat (MTX110)

in Preclinical Models of Adult Glioblastoma (ABSTRACT TMOD-27) - Lead Author: Dr David Ashley, Preston Tisch Brain Tumor Centre,

Duke University, Durham NC 27710

The Abstract may be found at:

The Poster may be found at:

Commenting, Steve Damment, EVP R&D

of Midatech, said: "These presentations provide further information on the encouraging Phase I DIPG trial results recently

announced by Midatech on 19 October 2020, and preclinical efficacy data supporting the potential utility of MTX110 for the significantly

larger adult glioblastoma indication."

MTX110 is a water-soluble

form of panobinostat free base, achieved through complexation with hydroxypropyl- -cyclodextrin (HPBCD), that enables convection-enhanced

delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour. Panobinostat is a hydroxamic acid and

acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor). The currently available oral formulation

of panobinostat lactate (Farydak ) is not suitable for treatment of brain cancers owing to poor blood-brain barrier penetration

and inadequate brain drug concentrations. Based on favourable translational science data, MTX110 is being evaluated

clinically as a treatment for DIPG (NCT03566199, NCT04264143) and recurrent medulloblastoma (NCT04315064), and preclinically for

treatment of glioblastoma (SNO 2020 Abstract TMOD-27). MTX110 is delivered directly into and around the patient's tumour via a

catheter system (e.g. CED or fourth ventricle infusions) to bypass the blood-brain barrier. This technique exposes the tumour to

very high drug concentrations while simultaneously minimising systemic drug levels and the potential for toxicity and other side

effects. Panobinostat has demonstrated high potency against DIPG tumour cells in in vitro and in vivo models, and

in a key study it was the most promising of 83 anticancer agents tested in 14 patient-derived DIPG cell lines (Grasso et al, 2015.

Nature Medicine 21(6), 555-559).

For more information, please contact:

Midatech Pharma PLC (dual listed on LSE

AIM: MTPH; and NASDAQ: MTP) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of

medicines. The Company combines approved and development medications with its proprietary and innovative drug delivery technologies

to provide compelling products that have the potential to powerfully impact the lives of patients.

The Company has developed three in-house

technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's

technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

The platform nature of the technologies

offers the potential to develop multiple drug assets rather than being reliant on a limited number of programmes. Midatech's

technologies are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. Midatech's

headquarters and R&D facility is in Cardiff, UK. For more information please visit www.midatechpharma.com.

Forward-Looking Statements

Certain statements in this press release

may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States

Private Securities Litigation Reform Act. All statements contained in this press release that do not relate to matters of historical

fact should be considered forward-looking statements.

Reference should be made to those documents

that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange

AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations

promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause

actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking

statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning

Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM

Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to

publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.